SHANK2-AS3: A Potential Drug Target Or Biomarker (G220070)

Target Name: SHANK2-AS3

NCBI ID: G220070

SHANK2-AS3

Other Name(s): C11orf76 | SHANK2 antisense RNA 3

SHANK2-AS3: A Potential Drug Target Or Biomarker

SHANK2-AS3 (C11orf76) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic variation has led to a range of biological processes that have been studied extensively, providing insights into its potential role in disease.

The SHANK2 gene is located on chromosome 11 and encodes a protein known as SHANK2, which is involved in a variety of cellular processes, including cell adhesion, migration, and invasion. SHANK2 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most significant studies on SHANK2 was conducted by a team of researchers at the University of California, San Diego, who identified a genetic variation in the SHANK2 gene that was associated with an increased risk of cancer. The researchers found that individuals with the variation had a higher likelihood of developing multiple types of cancer, including breast, ovarian, and prostate cancer.

Other studies have also shown that SHANK2 is involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These studies have identified a link between the SHANK2 gene and the production of beta-amyloid plaques, a hallmark of neurodegenerative disease, as well as a reduction in the levels of dopamine in the brain.

In addition to its role in disease, SHANK2 has also been shown to be a potential biomarker for cancer. Studies have shown that SHANK2 is expressed in a wide range of cancer types, including breast, ovarian, and prostate cancer. Additionally, research has shown that SHANK2 can be used as a biomarker for cancer recurrence, as individuals with recurrent cancer are often found to have reduced levels of SHANK2.

Despite the potential for SHANK2 as a drug target or biomarker, much more research is needed to fully understand its role in disease. Many researchers are currently studying the molecular mechanisms underlying SHANK2's role in disease, as well as exploring its potential as a drug or biomarker.

In conclusion, SHANK2-AS3 (C11orf76) is a gene that has been identified as a potential drug target or biomarker for a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic variation has led to a range of biological processes that have been studied extensively, providing insights into its potential role in disease. Further research is needed to fully understand the role of SHANK2 in disease and its potential as a drug or biomarker.

Protein Name: SHANK2 Antisense RNA 3

The "SHANK2-AS3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SHANK2-AS3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets